270 related articles for article (PubMed ID: 20307063)
1. Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists.
Blum CA; Caldwell T; Zheng X; Bakthavatchalam R; Capitosti S; Brielmann H; De Lombaert S; Kershaw MT; Matson D; Krause JE; Cortright D; Crandall M; Martin WJ; Murphy BA; Boyce S; Jones AB; Mason G; Rycroft W; Perrett H; Conley R; Burnaby-Davies N; Chenard BL; Hodgetts KJ
J Med Chem; 2010 Apr; 53(8):3330-48. PubMed ID: 20307063
[TBL] [Abstract][Full Text] [Related]
2. Pyrido[2,3-b]pyrazines, discovery of TRPV1 antagonists with reduced potential for the formation of reactive metabolites.
Hodgetts KJ; Blum CA; Caldwell T; Bakthavatchalam R; Zheng X; Capitosti S; Krause JE; Cortright D; Crandall M; Murphy BA; Boyce S; Brian Jones A; Chenard BL
Bioorg Med Chem Lett; 2010 Aug; 20(15):4359-63. PubMed ID: 20615696
[TBL] [Abstract][Full Text] [Related]
3. Novel vanilloid receptor-1 antagonists: 1. Conformationally restricted analogues of trans-cinnamides.
Norman MH; Zhu J; Fotsch C; Bo Y; Chen N; Chakrabarti P; Doherty EM; Gavva NR; Nishimura N; Nixey T; Ognyanov VI; Rzasa RM; Stec M; Surapaneni S; Tamir R; Viswanadhan VN; Treanor JJ
J Med Chem; 2007 Jul; 50(15):3497-514. PubMed ID: 17585749
[TBL] [Abstract][Full Text] [Related]
4. Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles.
Ognyanov VI; Balan C; Bannon AW; Bo Y; Dominguez C; Fotsch C; Gore VK; Klionsky L; Ma VV; Qian YX; Tamir R; Wang X; Xi N; Xu S; Zhu D; Gavva NR; Treanor JJ; Norman MH
J Med Chem; 2006 Jun; 49(12):3719-42. PubMed ID: 16759115
[TBL] [Abstract][Full Text] [Related]
5. Differential involvement of TRPV1 receptors at the central and peripheral nerves in CFA-induced mechanical and thermal hyperalgesia.
Kanai Y; Hara T; Imai A; Sakakibara A
J Pharm Pharmacol; 2007 May; 59(5):733-8. PubMed ID: 17524240
[TBL] [Abstract][Full Text] [Related]
6. Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate.
Doherty EM; Fotsch C; Bannon AW; Bo Y; Chen N; Dominguez C; Falsey J; Gavva NR; Katon J; Nixey T; Ognyanov VI; Pettus L; Rzasa RM; Stec M; Surapaneni S; Tamir R; Zhu J; Treanor JJ; Norman MH
J Med Chem; 2007 Jul; 50(15):3515-27. PubMed ID: 17585750
[TBL] [Abstract][Full Text] [Related]
7. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade.
Gavva NR; Bannon AW; Hovland DN; Lehto SG; Klionsky L; Surapaneni S; Immke DC; Henley C; Arik L; Bak A; Davis J; Ernst N; Hever G; Kuang R; Shi L; Tamir R; Wang J; Wang W; Zajic G; Zhu D; Norman MH; Louis JC; Magal E; Treanor JJ
J Pharmacol Exp Ther; 2007 Oct; 323(1):128-37. PubMed ID: 17652633
[TBL] [Abstract][Full Text] [Related]
8. Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity.
García-Martínez C; Fernández-Carvajal A; Valenzuela B; Gomis A; Van Den Nest W; Ferroni S; Carreño C; Belmonte C; Ferrer-Montiel A
J Pain; 2006 Oct; 7(10):735-46. PubMed ID: 17018334
[TBL] [Abstract][Full Text] [Related]
9. Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties.
Gomtsyan A; Bayburt EK; Schmidt RG; Zheng GZ; Perner RJ; Didomenico S; Koenig JR; Turner S; Jinkerson T; Drizin I; Hannick SM; Macri BS; McDonald HA; Honore P; Wismer CT; Marsh KC; Wetter J; Stewart KD; Oie T; Jarvis MF; Surowy CS; Faltynek CR; Lee CH
J Med Chem; 2005 Feb; 48(3):744-52. PubMed ID: 15689158
[TBL] [Abstract][Full Text] [Related]
10. Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management.
Gomtsyan A; Bayburt EK; Schmidt RG; Surowy CS; Honore P; Marsh KC; Hannick SM; McDonald HA; Wetter JM; Sullivan JP; Jarvis MF; Faltynek CR; Lee CH
J Med Chem; 2008 Feb; 51(3):392-5. PubMed ID: 18183945
[TBL] [Abstract][Full Text] [Related]
11. Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties.
Wang HL; Katon J; Balan C; Bannon AW; Bernard C; Doherty EM; Dominguez C; Gavva NR; Gore V; Ma V; Nishimura N; Surapaneni S; Tang P; Tamir R; Thiel O; Treanor JJ; Norman MH
J Med Chem; 2007 Jul; 50(15):3528-39. PubMed ID: 17585751
[TBL] [Abstract][Full Text] [Related]
12. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats.
Lehto SG; Tamir R; Deng H; Klionsky L; Kuang R; Le A; Lee D; Louis JC; Magal E; Manning BH; Rubino J; Surapaneni S; Tamayo N; Wang T; Wang J; Wang J; Wang W; Youngblood B; Zhang M; Zhu D; Norman MH; Gavva NR
J Pharmacol Exp Ther; 2008 Jul; 326(1):218-29. PubMed ID: 18420600
[TBL] [Abstract][Full Text] [Related]
13. (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo.
Surowy CS; Neelands TR; Bianchi BR; McGaraughty S; El Kouhen R; Han P; Chu KL; McDonald HA; Vos M; Niforatos W; Bayburt EK; Gomtsyan A; Lee CH; Honore P; Sullivan JP; Jarvis MF; Faltynek CR
J Pharmacol Exp Ther; 2008 Sep; 326(3):879-88. PubMed ID: 18515644
[TBL] [Abstract][Full Text] [Related]
14. Amelioration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect.
Watabiki T; Kiso T; Kuramochi T; Yonezawa K; Tsuji N; Kohara A; Kakimoto S; Aoki T; Matsuoka N
J Pharmacol Exp Ther; 2011 Mar; 336(3):743-50. PubMed ID: 21098091
[TBL] [Abstract][Full Text] [Related]
15. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats.
Honore P; Wismer CT; Mikusa J; Zhu CZ; Zhong C; Gauvin DM; Gomtsyan A; El Kouhen R; Lee CH; Marsh K; Sullivan JP; Faltynek CR; Jarvis MF
J Pharmacol Exp Ther; 2005 Jul; 314(1):410-21. PubMed ID: 15837818
[TBL] [Abstract][Full Text] [Related]
16. Eriodictyol: a flavonoid antagonist of the TRPV1 receptor with antioxidant activity.
Rossato MF; Trevisan G; Walker CI; Klafke JZ; de Oliveira AP; Villarinho JG; Zanon RB; Royes LF; Athayde ML; Gomez MV; Ferreira J
Biochem Pharmacol; 2011 Feb; 81(4):544-51. PubMed ID: 21087598
[TBL] [Abstract][Full Text] [Related]
17. N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain.
Pomonis JD; Harrison JE; Mark L; Bristol DR; Valenzano KJ; Walker K
J Pharmacol Exp Ther; 2003 Jul; 306(1):387-93. PubMed ID: 12721336
[TBL] [Abstract][Full Text] [Related]
18. Identification and biological characterization of 6-aryl-7-isopropylquinazolinones as novel TRPV1 antagonists that are effective in models of chronic pain.
Culshaw AJ; Bevan S; Christiansen M; Copp P; Davis A; Davis C; Dyson A; Dziadulewicz EK; Edwards L; Eggelte H; Fox A; Gentry C; Groarke A; Hallett A; Hart TW; Hughes GA; Knights S; Kotsonis P; Lee W; Lyothier I; McBryde A; McIntyre P; Paloumbis G; Panesar M; Patel S; Seiler MP; Yaqoob M; Zimmermann K
J Med Chem; 2006 Jan; 49(2):471-4. PubMed ID: 16420034
[TBL] [Abstract][Full Text] [Related]
19. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans.
Chizh BA; O'Donnell MB; Napolitano A; Wang J; Brooke AC; Aylott MC; Bullman JN; Gray EJ; Lai RY; Williams PM; Appleby JM
Pain; 2007 Nov; 132(1-2):132-41. PubMed ID: 17659837
[TBL] [Abstract][Full Text] [Related]
20. Identification and synthesis of 2,7-diamino-thiazolo[5,4-d]pyrimidine derivatives as TRPV1 antagonists.
Lebsack AD; Branstetter BJ; Hack MD; Xiao W; Peterson ML; Nasser N; Maher MP; Ao H; Bhattacharya A; Kansagara M; Scott BP; Luo L; Rynberg R; Rizzolio M; Chaplan SR; Wickenden AD; Guy Breitenbucher J
Bioorg Med Chem Lett; 2009 Jan; 19(1):40-6. PubMed ID: 19038548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
